Data / Drug companies / Dapagliflozin
Dapagliflozin: 26 companies and 52 products in the FDA NDC directory
Dapagliflozin is listed in the FDA National Drug Code Directory by 26 companies, with 52 products in commercial distribution. 42 of the products (80.8%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet, and the newest product started marketing on October 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 26
- Products
- 52
- Generic (ANDA) products
- 42 (80.8%)
- Application numbers
- 16
- Routes
- Oral
- Brand names
- Farxiga
- openFDA record search
- api.fda.gov
Companies that list dapagliflozin
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 6 | tablet, film coated | New drug applications (NDA) | April 6, 2026 |
| Ajanta Pharma USA Inc. | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Alembic Pharmaceuticals Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Alembic Pharmaceuticals Limited | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Ani Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | May 13, 2026 |
| Apotex Corp. | 2 | tablet, film coated | Generic drugs (ANDA) | April 8, 2026 |
| Ascend Laboratories, LLC | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| AstraZeneca Pharmaceuticals LP | 2 | tablet, film coated | New drug applications (NDA) | January 14, 2008 |
| Aurobindo Pharma Limited | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| AvKARE | 2 | tablet, film coated | Generic drugs (ANDA) | May 25, 2026 |
| Biocon Pharma Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | May 1, 2026 |
| Cipla USA Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Florida Pharmaceutical Products, LLC | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Lupin Pharmaceuticals, Inc. | 2 | tablet | Generic drugs (ANDA) | April 8, 2026 |
| Macleods Pharmaceuticals Limited | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Micro Labs Limited | 2 | tablet | Generic drugs (ANDA) | October 1, 2026 |
| Novadoz Pharmaceuticals LLC | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Prasco Laboratories | 2 | tablet, film coated | Authorized generics (NDA) | January 3, 2024 |
| Sandoz Inc | 2 | tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Teva Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | April 8, 2026 |
| Zydus Lifesciences Limited | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Zydus Pharmaceuticals USA Inc. | 2 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Bryant Ranch Prepack | 1 | tablet, film coated | Authorized generics (NDA) | January 3, 2024 |
| Bryant Ranch Prepack | 1 | tablet, film coated | Generic drugs (ANDA) | April 8, 2026 |
| Redpharm Drug | 1 | tablet | Generic drugs (ANDA) | April 6, 2026 |
| Remedyrepack Inc. | 1 | tablet, film coated | New drug applications (NDA) | April 23, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 37 | 71.2% |
| Tablet | 15 | 28.8% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 42 | 80.8% |
| New drug applications (NDA) | 5 | 9.6% |
| Authorized generics (NDA) | 5 | 9.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Sodium-Glucose Cotransporter 2 Inhibitor | 52 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.